ICIs are monoclonal antibodies targeting immune checkpoint molecules such as cytotoxic T-lymphocyte antigen-4 (CTLA-4), programmed cell death protein-1 (PD-1), and programmed cell death ligand-1 (PD-L1), thereby unleashing the immune system to attack tumor cells through T-cell activation [4]. Here, PDCD1 is linked to neoplasm.